ClinicalTrials.gg
CompletedNCT06238388Updated Aug 20, 2024

Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients

A Phase 1 interventional study of HSK21542 Injection in Chronic Kidney Disease Patients, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Oct 2023, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a single-center, nonrandomized, and open design study to investigate metabolism and excretion of HSK21542 in maintenance hemodialysis patients.

02

Conditions studied

  • Chronic Kidney Disease Patients
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are willing to sign an form, fully understand the objectives and purposes of the study, and are willing to comply with the study protocol before any of the study-related procedures start.
  2. Age ≥18 years old, Male or female;
  3. Patients with end-stage renal diseases who receive hemodialysis (including hemodiafiltration) 3 times in a week prior to screening for at least 3 months;
  4. Dry weight is 40.0-135.0 kg (inclusive) during the screening period;
  5. Patients with at least two occurrences of single-compartment urea clearance (sp Kt/V) ≥ 1.2, or at least two occurrences of urea reduction ratio (URR) ≥ 65%, or one occurrence of sp Kt/V ≥ 1.2 and one occurrence of URR ≥ 65% on different days of dialysis within 6 months before administration;
  6. Female of childbearing age or Male must agree to adopt efficient measures in sexual intercourse during the study period and within 3 months after the last administration; Menopausal female subjects should have had menopause at least one year or should have had permanent sterilization (e.g., fallopian tube occlusion, hysterectomy, bilateral salpingectomy).

Exclusion criteria

Exclusion Criteria:

  1. Expected to undergo kidney transplantation and/or parathyroidectomy during the study;
  2. History of allergy to opioids, such as urticaria (Note: adverse effects related to opioid use, such as constipation and nausea, are not included as the exclusion criteria in this study);
  3. Used opioids within 7 days before screening, or unable to avoid the use of opioids other than the product during the study;
  4. Participated in any clinical trial of other drug or medical device within 1 month before screening (received study medication or treated by the medical device in the clinical trial);
  5. Used blood perfusion during the screening period or expected study period;
  6. Blood pressure of upper limbs in the supine position at screening: systolic blood pressure \< 90 mmHg, or diastolic blood pressure \< 60 mmHg, or systolic blood pressure > 180 mmHg, or diastolic blood pressure > 110 mmHg;
  7. (ALT) or aspartate aminotransferase (AST)≥ 2.5 × (ULN), or total ≥ 2 × upper limit of normal (ULN) at screening;
  8. Blood sodium > 155 mmol/L at screening;
  9. Blood donation (or loss) ≥ 400 mL within the first 3 months of screening or \< 80 g/L at screening;
  10. Positive for surface antigen (HBsAg), antibody (HCVAb), syphilis antibody, or (HIV) antibody;
  11. Females who are pregnant or breastfeeding;
  12. Smoking an average of more than 5 cigarettes per day within the first 3 months of screening, or not stopping the use of any tobacco products during the trial period;
  13. Any physiological or psychological diseases or conditions that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's completion of the trial, as judged by the study physician, including but not limited to:

    1. Known or suspected alcohol, anesthetic, or other substance abuse or drug dependence history within the first 12 months of screening; Baseline urine drug screening (if any) or positive alcohol breath test;
    2. severe systolic or diastolic heart failure within the first 6 months of screening (e.g. grade IV congestive heart failure (NYHA heart function grading criteria can be found in Appendix 3) ;
    3. Severe mental illness or cognitive impairment (e.g., dementia);
    4. Any other relevant acute or chronic neurological and psychiatric diseases (e.g., encephalopathy, coma, delirium) within 3 months before screening And the researchers believe it is not suitable for enrollment;
    5. Patients with malignant tumors, but not including: curable cervical carcinoma in situ, skin basal cell carcinoma, or squamous cell carcinoma, or any other tumor that has been cured (with no evidence of disease recurrence within 5 years).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    0.8 μg/kg HSK21542 Injection

    0.8 μg/kg HSK21542 Injection

    Drug: HSK21542 Injection

Interventions

  • A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.

06

What researchers measure

Primary outcomes

  1. Cumulative recovery of unchanged drug (Ae)

    The pharmacokinetic parameters of HSK21542 in urine, feces, and dialysate

    Time frame: From the start of administration to 168 hours after administration

  2. Cumulative recovery fraction of unchanged drug (Fe)

    The pharmacokinetic parameters of HSK21542 in urine, feces, and dialysate

    Time frame: From the start of administration to 168 hours after administration

  3. Plasma clearance

    The pharmacokinetic parameters of HSK21542 in urine, feces, and dialysate

    Time frame: From the start of administration to 168 hours after administration

  4. Cmax

    The pharmacokinetic parameters of HSK21542 in plasma

    Time frame: From the start of administration to 168 hours after administration

  5. AUC(0-t)

    The pharmacokinetic parameters of HSK21542 in plasma

    Time frame: From the start of administration to 168 hours after administration

  6. AUC(0-∞)

    The pharmacokinetic parameters of HSK21542 in plasma

    Time frame: From the start of administration to 168 hours after administration

  7. Tmax

    The pharmacokinetic parameters of HSK21542 in plasma

    Time frame: From the start of administration to 168 hours after administration

  8. t1/2

    The pharmacokinetic parameters of HSK21542 in plasma

    Time frame: From the start of administration to 168 hours after administration

Secondary outcomes

  1. The main metabolites of HSK21542

    The main metabolites of HSK21542 in plasma, urine, feces, and dialysate

    Time frame: From the start of administration to 168 hours after administration

  2. Adverse events (AEs)

    The incidence and severity of AEs

    Time frame: From after administration to the end of telephone follow-up

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
    Jinan, Shandong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Nov 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2024
First posted
Feb 2, 2024
StartActual
Oct 10, 2023
Primary completionActual
Nov 21, 2023
CompletionActual
Feb 27, 2024
Last update
Aug 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06238388
Responsible party
Sponsor
First posted
Feb 2, 2024
Start date
Oct 10, 2023
Primary completion
Nov 21, 2023
Completion
Feb 27, 2024
Last update
Aug 20, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK21542

Start the discussion